CTOs on the Move

SafeGraph

www.safegraph.com

 
SafeGraph graphs datasets together to solve humanity`s biggest secrets.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

SafeGraph raised $16M on 04/19/2017
SafeGraph raised $45M on 03/16/2021

Similar Companies

Reachdesk

Unlock the power of gifting at scale with Reachdesk, the world’s #1 global corporate gifting platform built for revenue success.

Dirxion

As a leader in online publications, Dirxion provides custom interfaces for e-catalogs, interactive directories and other publishing industries.

Daasity

Daasity helps over 1,600 consumer product brands unlock data-driven growth. One product. One data set. One view. Limitless potential. With Daasity, it’s one and done. Daasity is the only business insights solution built for direct-to-consumer brands by...

RedShelf

RedShelf is an EdTech company focused on helping publishers, schools, and businesses transition effortlessly to more affordable and efficient digital textbooks and course materials. In addition to digitizing and distributing content from thousands of publishers and content providers, we offer an end-to-end software platform (our Content Delivery System) that streamlines every step in the course material acquisition and distribution process. We`ve become one of the nation`s fastest-growing education companies because we`re a true one-stop-shop, offering the most modern technology and unparalleled support to help our partners adapt and thrive in the digital age.

Kapost

Juventas Therapeutics is a private clinical-stage company developing novel therapies for ischemic cardiovascular disease. The company`s lead product` JVS-100` is a non-viral plasmid that encodes for stromal cell-derived factor-1 (SDF-1). SDF-1 has been shown to significantly increase end-organ function following tissue injury by promoting cell survival` recruiting endogenous stem cells to the damaged region` and promoting new blood vessel growth. The SDF-1 repair pathway is well conserved throughout end-organ systems providing the opportunity to impact a broad range of diseases. Target cardiovascular clinical indications address large markets with high unmet medical need and significant market potential. Juventas is currently enrolling multiple clinical trials to test therapy efficacy in heart failure and critical limb ischemia patients.